Topline Phase 3 Data: Upadacitinib (Rinvoq, AbbVie) Continues to Show Promise in Severe AA
Upadacitinib (Rinvoq, AbbVie) achieved the primary endpoint in the second of two pivotal studies in patients with severe alopecia areata (AA), according to new topline results from the Phase 3 UP-AA clinical program.